AQEMIA
AQEMIA, a leading company in generative-AI-driven drug discovery, announces the achievement of a research milestone in its collaboration with Servier, an international independent pharmaceutical company, to address an undruggable target in immuno-oncology.
Based on AQEMIA ‘s quantum and statistical physics-based calculations, and within the span of a few months, a series of molecules experimentally active on an undruggable target in immuno-oncology have been successfully identified. This milestone triggers an undisclosed payment to AQEMIA.
"Our teams are very proud of this achievement that demonstrates the power of AQEMIA's cutting-edge generative AI and deep physics in creating novel, patentable molecules to meet therapeutic needs that are still immense, particularly in the field of immuno-oncology. Within the framework of our collaboration with Servier, we have reached the stage where a series of molecules are subsequently proven impactful in vitro and in vivo assays. " said Maximilien Levesque, PhD, CEO and Co-founder of AQEMIA.
This critical milestone is a continuation of Servier and AQEMIA’s successful partnership program, initiated in December 2021, to accelerate drug candidate discovery in immuno-oncology using artificial intelligence and deep physics.
AQEMIA has worked on more than a dozen in-house therapeutic programs in oncology and immuno-oncology, as well as in new therapeutic areas such as immunology, inflammation and diseases of the central nervous system. To date, AQEMIA’s three most advanced programs are being tested against cancers in animals.
About AQEMIA
AQEMIA is a next-gen techbio generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast many innovative drug candidates for critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms to power a generative artificial intelligence designing novel drug candidates, without the need to train on experimental data. We already delivered several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies - most advanced programs being currently in vivo optimization.
For more information, visit AQEMIA.com and our LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627468833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Announces Secondary Offering of Class A Common Stock by Selling Stockholders4.11.2025 22:47:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces that trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) propose to sell 11,301,323 shares of the Company’s Class A Common Stock, par value $.01 per share, through a proposed registered public offering (the “Offering”). The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of the Lauder family will beneficially own, directly or indirectly, 82% of the outstanding voting power of the Company’s Common Stock. The Selling S
New Global Survey Reveals Oracle Database Customers are Evolving their Database Strategies Citing High Costs, Support Challenges and Need for Advanced AI/ML Capabilities4.11.2025 21:43:00 CET | Press release
Third-party support provides Oracle Database customers with significant cost savings and premium support, allowing organizations to focus their resources toward AI/ML and LLM initiatives Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the findings of the 2025 Database Strategies and Support Survey – The Diversification and Decentralization Revolution, a global study conducted by Unisphere Research of more than 200 Oracle Database managers and practitioners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104640087/en/ New Global Survey Reveals Oracle Database Customers are Evolving their Database Strategies Citing High Costs, Support Challenges and Need for Advanced AI/ML Capabilities Oracle Database Customers Face Suppor
TRU Simulation receives Japanese Civil Aviation Bureau qualification for the SUBARU Bell 412EPX Flight Training Device, delivering next-level realism to rotorcraft training operators in Japan4.11.2025 21:30:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Bell Textron Inc., today announced the SUBARU Bell 412EPX Flight Training Device (FTD) has received Level 5 qualification from the Japanese Civil Aviation Bureau (JCAB), marking a significant milestone in advancing rotorcraft training capabilities in Japan. Developed in collaboration with Bell, the FTD supports SUBARU’s mission in civil aviation by enabling pilots to train for a wide range of operations—from routine transport to complex search and rescue (SAR) missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104983178/en/ TRU Simulation receives Japanese Civil Aviation Bureau qualification for the SUBARU Bell 412EPX Flight Training Device, delivering next-level realism to rotorcraft training operators in Japan “SUBARU pilots flying some of Japan’s most critical missions now have access to immersive, high-fidelity training that b
PennAero and Tinicum Announce Acquisition of TriMas Aerospace4.11.2025 20:17:00 CET | Press release
Tinicum, L.P. (“Tinicum”) today announced that one of its affiliates has signed an agreement to acquire the aerospace assets of TriMas Corporation (“TriMas Aerospace”), through which TriMas Aerospace will be merged with PennAero, a Tinicum portfolio company (“the Transaction”). Funds managed by Blackstone will be a minority investor in the Transaction. This investment reinforces PennAero’s strategy of partnering with its customers to provide best-in-class engineering, manufacturing, customer service and support. TriMas Aerospace is a leading provider of highly engineered fasteners and precision-machined components for mission-critical applications across the global commercial aerospace and defense industries. Backed by a portfolio of trusted brands, including Monogram Aerospace Fasteners™, Allfast Fastening Systems®, Mac Fasteners™, TFI Aerospace, TriMas Aerospace Germany, Martinic Engineering™, RSA Engineered Products™ and Weldmac Manufacturing Company, TriMas Aerospace delivers innov
BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia4.11.2025 19:50:00 CET | Press release
In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreement to localize the manufacture of two biosimilar medicines within the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104239476/en/ Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncology Arabia at the Global Health Exhibition 2025 in Riyadh, following the signing of an agreement to localize the manufacturing of advanced biologic medicines. The partnership builds on Boston Oncology Arabia’s fully integrated Saudi operations and its leadership in transferring global biopharma expertise to strengthen national drug security, expand local value creation, and deliver sustainable access to high-quality biologic therapies in line with Vision 2030. The signing ceremony took place
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom